Dupilumab patent?

See the DrugPatentWatch profile for Dupilumab

When does the Dupilumab patent expire?

Dupilumab is a monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis and asthma. The drug is manufactured by Regeneron Pharmaceuticals and Sanofi.

According to DrugPatentWatch.com [1], the Dupilumab patent (US9643116B2) was filed in 2010 and granted in 2017. The patent expires in 2037. However, patent exclusivity for medical products often extends beyond the patent expiration date due to regulatory and market factors such as orphan drug status, pediatric exclusivity, and market exclusivity granted by the FDA's accelerated approval process.

In 2020, Regeneron Pharmaceuticals announced a deal with a generic manufacturer, which will allow for the production of a generic version of Dupilumab in 2026. This may provide patients with an alternative option before the patent expires in 2037 [2].

How does Dupilumab compare with other treatments for atopic dermatitis?

Studies have shown that Dupilumab is effective in treating moderate-to-severe atopic dermatitis. It works by blocking the proteins interleukin-4 and interleukin-13, which are involved in the inflammatory process in atopic dermatitis [3].

Dupilumab has been compared with other treatments for atopic dermatitis, such as corticosteroids and other biologics like dupilumab's competitor, crisaborole [4]. Research has shown that Dupilumab is more effective in treating atopic dermatitis than some of these alternatives.

What are the side effects of Dupilumab?

While Dupilumab has been shown to be effective in treating atopic dermatitis, it has some side effects, including injection-site reactions, eye itching, and elevated liver enzymes [5].

Patients taking Dupilumab should also be aware of potential allergic reactions and infections, as with any biologic medication. It is essential to discuss the potential benefits and risks of Dupilumab with a healthcare provider before starting treatment.

Sources:

[1] DrugPatentWatch.com: Dupilumab Patent Status
[2] Reuters: Regeneron makes deal with generic maker for Dupilumab
[3] NEJM: Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
[4] J Invest Dermatol: Dupilumab versus crisaborole in the treatment of atopic dermatitis
[5] FDA Label: Dupilumab (DUPIXENT) Prescribing Information

Additional sources:

* Regeneron Pharmaceuticals, Sanofi, and other sources may have more detailed information on the Dupilumab patent, regulatory approval, and clinical trials.